This PA is intended to provide investigators with rapid access to support for pilot, Phase I, and Phase II cancer clinical trials as well as patient monitoring and laboratory studies. The focus of this QUICK-TRIAL PA is on translational research in new agent or device development to ensure the timely exploitation of new cancer therapeutic. This PA is aimed at providing a new approach in the grant application process by offering a rapid turnaround from application submission to funding. Features of this initiative include a modular grant application and award process, inclusion of the clinical protocol within the grant application, and accelerated peer review with the goal of issuing new awards within six months of application receipt. In addition, QUICK-TRIAL applications do not require extensive preliminary data in the grant application and support exploratory translational and clinical research studies involving cancer prevention, chemotherapy and rapid development and application of novel clinical cancer therapies including image guided therapeutic procedures. Investigators may apply for a maximum of two years of funding support using the exploratory or developmental (R21) grant mechanism for up to $250,000 direct costs per year.

• Release Date: October 7, 2002
• Application Receipt Date(s): December 9, 2002, April 9, 2002, August 11, 2003, December 9, 2003, April 9, 2004, August 9, 2004
• Contact: Keyvan Farahani, Ph.D. (farahank@mail.nih.gov) at 301-451-2651

See full description in NIH Guide: PAR-03-005